 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- | MIT-001 / MitoImmune Therap
Preclinical, Journal: In vitro broad-spectrum antiviral activity of MIT-001, a mitochondria-targeted reactive oxygen species scavenger, against severe acute respiratory syndrome coronavirus 2 and multiple zoonotic viruses. (Pubmed Central) - Mar 4, 2024
The presence of MIT-001 also alleviated mitochondrial depolarization caused by SARS-CoV-2 infection. These findings highlight the potential of MIT-001 as a broad-spectrum antiviral compound that targets for zoonotic RNA and DNA viruses, providing a promising therapeutic approach to combat viral infection.
- MIT-001 / MitoImmune Therap
Evaluation of the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_2667;
MIT-001 was administered intravenously for 30 minutes once daily before conditioning chemotherapy for four to nine days, depending on the conditioning regimens including high-dose melphalan and BMT (intravenous busulfan, melphalan, thiotepa) for auto-HSCT. The phase IIa part 1 results strongly suggest the therapeutic potential of MIT-001 to prevent severe OM in the patients with lymphoma and MM undergoing melphalan-containing conditioning followed by auto-HSCT.
- || MIT-001 / MitoImmune Therap
Trial completion: Clinical Trial to Evaluate Pharmacokinetic Characteristics of MIT-001 After SC Administration in Healthy Subjects (clinicaltrials.gov) - Aug 24, 2023
P1, N=40, Completed, Sponsor: MitoImmune Therapeutics
The phase IIa part 1 results strongly suggest the therapeutic potential of MIT-001 to prevent severe OM in the patients with lymphoma and MM undergoing melphalan-containing conditioning followed by auto-HSCT. Active, not recruiting --> Completed
- | MIT-001 / MitoImmune Therap
Journal: Alleviation of hippocampal necroptosis and neuroinflammation by NecroX-7 treatment after acute seizures. (Pubmed Central) - Aug 21, 2023
Thus, we investigated the therapeutic effects of a novel small molecule, NecroX-7, in TLE using both a low [Mg]-induced epileptiform activity model and a mouse model of pilocarpine-induced status epilepticus (SE)...Finally, western blot analysis demonstrated that NecroX-7 post-treatment after acute seizures could decrease the expression of mixed lineage kinase domain-like pseudokinase (MLKL) and phosphorylated MLKL (p-MLKL), markers for necroptosis. Taken all together, NecroX-7 has potential as a novel medication for TLE with its neuroprotective, anti-inflammatory, and anti-necroptotic effects.
- || MIT-001 / MitoImmune Therap
Trial completion date, Trial primary completion date, Metastases: MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients (clinicaltrials.gov) - Apr 24, 2023
P2, N=60, Recruiting, Sponsor: MitoImmune Therapeutics
Taken all together, NecroX-7 has potential as a novel medication for TLE with its neuroprotective, anti-inflammatory, and anti-necroptotic effects. Trial completion date: Sep 2023 --> Dec 2024 | Trial primary completion date: Sep 2022 --> Apr 2024
- || MIT-001 / MitoImmune Therap
Enrollment closed: Clinical Trial to Evaluate Pharmacokinetic Characteristics of MIT-001 After SC Administration in Healthy Subjects (clinicaltrials.gov) - Mar 21, 2023
P1, N=40, Active, not recruiting, Sponsor: MitoImmune Therapeutics
Trial completion date: Sep 2023 --> Dec 2024 | Trial primary completion date: Sep 2022 --> Apr 2024 Recruiting --> Active, not recruiting
- | MIT-001 / MitoImmune Therap
Preclinical, Journal: The Effect of Necrosis Inhibitor on Dextran Sulfate Sodium Induced Chronic Colitis Model in Mice. (Pubmed Central) - Jan 22, 2023
Overall, the NI improved DSS induced chronic colitis by attenuating the mRNA expression of pro-inflammatory cytokines such as TNF-α. Therefore, NI use is a potential, novel treatment approach for IBD.
- |||| MIT-001 / MitoImmune Therap
New P2a trial: Capella: Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT (clinicaltrials.gov) - Aug 9, 2022
P2a, N=75, Recruiting, Sponsor: MitoImmune Therapeutics
- || MIT-001 / MitoImmune Therap
Enrollment open: Clinical Trial to Evaluate Pharmacokinetic Characteristics of MIT-001 After SC Administration in Healthy Subjects (clinicaltrials.gov) - Jun 8, 2022
P1, N=40, Recruiting, Sponsor: MitoImmune Therapeutics
Therefore, NI use is a potential, novel treatment approach for IBD. Not yet recruiting --> Recruiting
- || MIT-001 / MitoImmune Therap
New P1 trial: Clinical Trial to Evaluate Pharmacokinetic Characteristics of MIT-001 After SC Administration in Healthy Subjects (clinicaltrials.gov) - May 24, 2022
P1, N=40, Not yet recruiting, Sponsor: MitoImmune Therapeutics
- ||| MIT-001 / MitoImmune Therap
Enrollment open, Trial completion date, Trial primary completion date, Metastases: MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients (clinicaltrials.gov) - Dec 2, 2021
P2, N=60, Recruiting, Sponsor: MitoImmune Therapeutics
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: Apr 2023 --> Sep 2023 | Trial primary completion date: May 2022 --> Sep 2022
- | MIT-001 / MitoImmune Therap
Journal: MIT-001 Restores Human Placenta-Derived Mesenchymal Stem Cells by Enhancing Mitochondrial Quiescence and Cytoskeletal Organization. (Pubmed Central) - Jun 10, 2021
In conclusion, while TNF-α/IFN-γ-exposed MSCs lost homeostasis and mitochondrial quiescence by becoming over-activated in response to inflammatory cytokines, MIT-001 was able to rescue mitochondrial features and cellular phenotypes. Therefore, MIT-001 has therapeutic potential for clinical applications to treat mitochondrion-related inflammatory diseases.
- | MIT-001 / MitoImmune Therap
New P2 trial, Metastases: MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients (clinicaltrials.gov) - Dec 3, 2020
P2, N=60, Not yet recruiting, Sponsor: MitoImmune Therapeutics
- | MIT-001 / MitoImmune Therap
Trial completion: A Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of LC28-0126. (clinicaltrials.gov) - Apr 11, 2018
P1, N=32, Completed, Sponsor: LG Chem
Therefore, MIT-001 has therapeutic potential for clinical applications to treat mitochondrion-related inflammatory diseases. Recruiting --> Completed
- | MIT-001 / MitoImmune Therap
New P1 trial: A Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of LC28-0126. (clinicaltrials.gov) - Jun 22, 2017
P1, N=32, Recruiting, Sponsor: LG Chem
- ||||| MIT-001 / MitoImmune Therap
New P2 trial: Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI Patients (clinicaltrials.gov) - May 12, 2016
P2, N=100, Recruiting, Sponsor: LG Life Sciences
- |||| MIT-001 / MitoImmune Therap
Trial completion: Phase 2 Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI Patients (clinicaltrials.gov) - May 10, 2016
P2, N=60, Completed, Sponsor: LG Life Sciences
Recruiting --> Completed Active, not recruiting --> Completed
- ||| MIT-001 / MitoImmune Therap
Enrollment closed, Trial primary completion date: Phase 2 Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI Patients (clinicaltrials.gov) - Sep 18, 2015
P2, N=60, Active, not recruiting, Sponsor: LG Life Sciences
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jun 2015
- ||| MIT-001 / MitoImmune Therap
Trial completion: Study to Investigate the Safety and Pharmacokinetic Characteristics of LC28-0126 in Healthy Male Subjects (clinicaltrials.gov) - Mar 12, 2014
P1, N=89, Completed, Sponsor: LG Life Sciences
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jun 2015 Recruiting --> Completed
- ||||| MIT-001 / MitoImmune Therap
New P2 trial: Phase 2 Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI Patients (clinicaltrials.gov) - Feb 23, 2014
P2, N=60, Recruiting, Sponsor: LG Life Sciences
- ||| MIT-001 / MitoImmune Therap
New P1 trial: Study to Investigate the Safety and Pharmacokinetic Characteristics of LC28-0126 in Healthy Male Subjects (clinicaltrials.gov) - Nov 27, 2012
P1, N=89, Completed, Sponsor: LG Life Sciences